Factors involved in progression to cirrhosis
TB, cirrhosis, non-cirrhosis, end-stage liver disease
REGRESSION, CIRRHOSIS
In the training cohort, 81 (44.3%) patients developed cirrhosis within 360 days, and 102 (55.7%) patients were not affected with cirrhosis. Table Comparison of the baseline characteristics between cirrhosis and non-cirrhosis groups in the training cohort.SD, standard deviation; IQR, interquartile range; BMI, body mass index; PMI, psoas muscle index; WBC, white blood cell count; NLR, neutrophil-to-lymphocyte ratio; HB, hemoglobin; PLT, platelet; INR, International normalized ratio; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, alanine aminotransferase; GGT, glutamyl transpeptidase; ALP, alkaline phosphatase; ChE, cholinesterase; Na, Serum sodium; CR, serum creatinine; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein.We performed univariate and multivariate logistic regression analysis to find possible variables connected to the long-term development to cirrhosis in HBV-ACLF patients. Age, PMI, WBC, NLR, INR, TB, ALB, ChE, Na, and AFP were significantly linked with progression to cirrhosis in ACLF patients, according to the results of the univariate analysis (P < 0.05), as presented in Table Univariate and multivariate regression analysis of cirrhosis in the training cohort.BMI, body mass index; PMI, psoas muscle index; WBC, white blood cell count; NLR, neutrophil-to-lymphocyte ratio; HB, hemoglobin; PLT, platelet; INR, International normalized ratio; TB, total bilirubin; ALB, albumin; ALT, alanine aminotransferase; AST, alanine aminotransferase; GGT, glutamyl transpeptidase; ALP, alkaline phosphatase; ChE, cholinesterase; Na, Serum sodium; CR, serum creatinine; AFP, alpha-fetoprotein; OR, odds ratio; CI, confidence interval.